APEIRON Capital’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
APEIRON Capital's SMMT Position: Q3 2026 in Review
APEIRON Capital sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 961,866 shares — an estimated $14M sold.
APEIRON Capital first reported a position in SMMT in Q2 2025 and held it in 5 quarters. The position peaked at $27.1M in Q3 2025. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- APEIRON Capital reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- APEIRON Capital sold 961,866 Summit Therapeutics shares in Q3 2026, an estimated $14M.
- APEIRON Capital first reported a position in Summit Therapeutics in Q2 2025 and held it in 5 quarters.
- APEIRON Capital's Summit Therapeutics position peaked at $27.1M in Q3 2025.
- 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on APEIRON Capital's 13F filing for Q3 2026, filed 4 Nov 2026.